Pathophysiological changes reported in the elderly include increased platelet activation and reactivity, elevated levels of coagulation factors and plasminogen activator inhibitor type-1, and decreased bleeding time—all consistent with an increased risk for thrombosis. However, elderly patients with coronary artery disease (CAD) also encounter an increased risk of bleeding during antiplatelet t...

BACKGROUND Diabetes mellitus type 2 (DM2) is associated with high platelet reactivity both in patients who do not receive antiplatelet drugs and in those treated with acetylsalicylic acid (ASA). The pathomechanism of this phenomenon has not been fully understood. AIM 1. To evaluate variability of platelet reactivity in patients with DM2 treated with oral antidiabetic drugs and receiving chron...

BACKGROUND Patients with type 2 diabetes mellitus (T2DM) have reduced aspirin-induced pharmacodynamic effects. This may be attributed to increased platelet turnover rates resulting in an increased proportion of non-aspirin-inhibited platelets during the daily dosing interval. The hypothesis of this study was that an increase in the frequency of drug administration [twice daily (bid) versus once...

The article on antiplatelet drug resistance by Drs. Burns, Mooss, and Hilleman 1 was an excellent, yet cautionary, review that had several points that we feel deserve comment. First, the authors included a point-of-care measure of platelet function that could be more completely explained—the VerifyNow instrument (Accumetrics, San Diego, CA). This assay is for three types of platelet inhibition:...

We have read the article by Tekkesin et al. (1) entitled “The first six-month clinical outcomes and risk factors associated with high on-treatment platelet reactivity of clopidogrel in patients undergoing coronary interventions” published in Anatol J Cardiol 2016; 16: 967-73 with great interest. A meta-analysis of 17 studies consisting of 20839 patients indicated that clopidogrel-treated patien...

BACKGROUND Ticagrelor and prasugrel provide stronger platelet inhibition compared with clopidogrel. Direct pharmacodynamic comparison between them has not yet been reported in ST-segment-elevation myocardial infarction patients. METHODS AND RESULTS In a prospective, single-center, single-blind study, 55 out of 117 (47%) screened consecutive ST-segment-elevation myocardial infarction patients ...

OBJECTIVES This study sought to evaluate the platelet response to aspirin and the immature platelet fraction in patients with previous stent thrombosis (ST). BACKGROUND ST is a potentially fatal complication of coronary stenting. A reduced platelet response to aspirin increases the risk of cardiovascular events. METHODS We included 117 patients previously undergoing percutaneous coronary in...

BACKGROUND Dual therapy with aspirin and clopidogrel has emerged as the gold standard therapy for patients treated with drug-eluting stents (DES). However, there is variability in patients' responses to this antiplatelet therapy, and some patients continue to show ischemic recurrences after therapy. The purpose of the study was to compare the simultaneously obtained results of various platelet-...